Neurology
Focal Dystonia
7
Pipeline Programs↗
0
Active Trials↗
5
Companies Involved↗
Focal Dystonia is an early-stage landscape with 7 programs across 5 companies. The most active players are Purdue Pharma LP, Boehringer Ingelheim, Viatris Specialty LLC. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 11
Phase 22
Phase 3
No programs
Approved1
Analysis
Trial Status
4
clinical trials
Completed4 · 100%
Clinical Trials
Trial Activity
Mexiletine for the Treatment of Focal Dystonia
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00001784·24 enrolled
Amlodipine Plus Botulinum Toxin for Focal Dystonia
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00015457·16 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)